Abstract:Introduction Recent clinical and preclinical evidences suggested that neuroinflammation is a key factor which interacts with the neurobiological correlates of major depressive disorder, which are the (i) dysregulation of the hypothalamic-pituitary-adrenal axis, (ii) depletion of brain serotonin and (iii) alteration of neurogenesis in the dentate gyrus of the hippocampus. The gut bacterial has major impact on the brain development, behaviour and host immune system through the microbiota-gut-brain axis. Objectives The objective of the research is to establish the role inflammation induced by gut dysbiosis plays in behavioural changes of patients suffering from major depressive disorders. Methods Clinical data and preclinical experiments were used to elucidate the role gastrointestinal bacterial play in the development and functional physiology of the nervous system and because of the bidirectional communication between the enteric nervous system in the gut and the central nervous system, through the vagal plexus, blood circulation and endocrine system; it was discovered that the appropriate population of intestinal microbiota affect the immunological state of the brain. Results The intestinal microbiota has been able to maintain the attenuation and regulation of pro-inflammatory biomarkers in the brain and such had assisted in the healthy state of the brain; however, a disruption of gastrointestinal organisms in a condition called dysbiosis could result in breakdown of protective gastrointestinal mucosa barrier resulting in leaky gut and consequently, the permeability of the gut lining and migration of some bacteria, to the brain through the vagal networks and other channels. These pathophysiological cascades appear to be triggered or sustained and reinforced by chronic inflammatory condition involving increased circulating markers of inflammation, which are able to cross the blood brain barrier to activate the microglia. Conclusions Studies in depression suggest that inflammatory biomarkers such as C-reactive protein can be used to enrich samples for anti-inflammatory clinical trials for depression that target inflammation-related symptoms such as anhedonia and anxiety. Although, still at the developmental stages, imaging of neuroinflammation will help establish a target in the brain to further facilitate the testing of anti-inflammatory therapies for depression. Disclosure of Interest None Declared

Inflammation, Lifestyle Factors, and the Microbiome‐Gut‐Brain Axis: Relevance to Depression and Antidepressant Action

Gut microbiota–brain axis in depression: The role of neuroinflammation

Gut-brain axis: A matter of health and disease in neuropsychiatric disorders…!

Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets

Intestinal Barrier, Immunity and Microbiome: Partners in the Depression Crime

Gut Microorganisms, Neuroinflammation and Behavioral Changes

The brain-gut-microbiota interplay in depression: A key to design innovative therapeutic approaches

A Reciprocal Link Between Gut Microbiota, Inflammation and Depression: A Place for Probiotics?

Nutritional Modulation of the Gut–Brain Axis: A Comprehensive Review of Dietary Interventions in Depression and Anxiety Management

Mood and Microbes: a Comprehensive Review of Intestinal Microbiota’s Impact on Depression

Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment

Gut-to-brain axis provides novel therapeutic targets for depression

Depressed gut? The microbiota-diet-inflammation trialogue in depression

The Gut Microbiota Links Dietary Polyphenols With Management of Psychiatric Mood Disorders

Prebiotic and Probiotic Modulation of the Microbiota–Gut–Brain Axis in Depression

The Microbiota-Gut-Brain Axis: A New Direction in Research on Depression

Gut-brain axis in depression: Crosstalk between neuroinflammation and gut microbiota

The Microbiota–Gut–Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect

Microbes and mood: innovative biomarker approaches in depression

Brain–gut–microbiota axis in depression: A historical overview and future directions

BDNF/CREB signaling pathway contribution in depression pathogenesis: A survey on the non-pharmacological therapeutic opportunities for gut microbiota dysbiosis